Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug–drug interaction predictions using a PBPK approach

S Bhatnagar, D Mukherjee, AH Salem, D Miles… - Cancer Chemotherapy …, 2021 - Springer
Purpose Venetoclax, a targeted anticancer agent approved for the treatment of chronic
lymphocytic leukemia and acute myeloid leukemia, is a substrate of cytochrome P450 (CYP) …
被引用次数：25 相关文章

Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug-drug interaction predictions using a PBPK approach

S Bhatnagar, D Mukherjee… - Cancer …, 2021 - pubmed.ncbi.nlm.nih.gov
Purpose Venetoclax, a targeted anticancer agent approved for the treatment of chronic
lymphocytic leukemia and acute myeloid leukemia, is a substrate of cytochrome P450 (CYP) …

Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug-drug interaction predictions using a PBPK approach.

S Bhatnagar, D Mukherjee, AH Salem… - Cancer …, 2021 - europepmc.org
Purpose Venetoclax, a targeted anticancer agent approved for the treatment of chronic
lymphocytic leukemia and acute myeloid leukemia, is a substrate of cytochrome P450 (CYP) …

Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug–drug interaction predictions using a PBPK approach.

S Bhatnagar, D Mukherjee, AH Salem… - Cancer …, 2021 - search.ebscohost.com
Purpose: Venetoclax, a targeted anticancer agent approved for the treatment of chronic
lymphocytic leukemia and acute myeloid leukemia, is a substrate of cytochrome P450 (CYP) …

Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug–drug interaction predictions using a PBPK approach

B Sumit, M Dwaipayan, SA Hamed… - Cancer …, 2021 - search.proquest.com
Purpose Venetoclax, a targeted anticancer agent approved for the treatment of chronic
lymphocytic leukemia and acute myeloid leukemia, is a substrate of cytochrome P450 (CYP) …